Kemira Q1 2026 slides: revenue falls 4%, profitability pressured By Investing.com

Kemira’s Q1 2026 results missed expectations, with revenue down 4% to EUR 677 million, organic revenue down 3%, and operative EBITDA falling to EUR 117.3 million as margin compressed 180 bps to 17.3%. EPS declined 24% to EUR 0.29 versus roughly EUR 0.32 expected, while currency headwinds reduced revenue by EUR 26 million and EBITDA by EUR 3.1 million. Despite the weak quarter, the company kept full-year guidance unchanged at EUR 2.6-3.0 billion of revenue and EUR 470-570 million of operative EBITDA, and shares fell 8.33% after the presentation.

Analysis

Kemira is a good read-through on how a seemingly benign macro slowdown can become a margin problem when input inflation is lagged and pricing power is deferred. The first-order damage is already visible, but the second-order issue is that mix and timing matter: the weakest segment is also the one with the least ability to reprice quickly, so near-term earnings revisions are likely to lag the stock’s initial selloff by one to two quarters if energy and logistics stay elevated.

The bigger winner from this setup is not necessarily a direct competitor but any supplier with a more domestic cost base or a shorter pass-through cycle. In specialty chemicals, the market often underestimates working-capital release as a compensating mechanism; Kemira’s cash conversion improvement suggests the P&L pain may be partially masked by balance-sheet resilience, which can delay a full de-rating. That said, if end-market demand does not stabilize by mid-year, cash flow strength will likely be redirected to protecting the dividend/buyback rather than incremental growth, limiting upside optionality.

The key catalyst is whether pricing actions catch up before the raw-material lag fully hits the second quarter. If energy prices fade and FX headwinds ease, margins can snap back quickly because the company is operating with enough leverage to benefit from even modest volume recovery. If not, the risk is a classic squeeze: weaker demand, higher costs, and disappointing guidance credibility that can keep valuation under pressure for months.

Consensus may be underestimating how much of this is timing versus terminal deterioration. The stock reaction implies the market is pricing in a structural reset, but the stronger balance sheet and continued M&A suggest management still sees a cyclical dislocation rather than a broken franchise. That makes the setup more interesting for relative-value trades than outright directional shorts.

Key Decisions for Investors

• Short KEMIRA on rallies over the next 2-6 weeks; use the Q1 miss to fade any bounce until evidence of pricing recovery appears. Risk/reward favors downside if Q2 prints before cost pass-through fully materializes.
• Pair trade: long a domestic, faster-pass-through specialty/industrial chemicals name vs. short KEMIRA for the next 1-2 quarters. The edge is shorter pricing latency and lower FX leakage.
• Buy downside protection via 3-6 month put spreads rather than outright short if liquidity is a constraint. The setup has event risk around guidance credibility and could re-rate sharply if macro stabilizes.
• Avoid adding to cyclical packaging/paper-exposed industrials until there is clearer evidence of end-demand inflection; the issue is not just demand but that margin recovery lags by roughly one reporting cycle.
• If oil and logistics costs roll over, take profits on any short exposure quickly; the thesis can unwind fast because Kemira’s working-capital and pricing mechanisms can improve reported cash flow before earnings do.